COVID-19 'Treatment' study pulled before a single volunteer signed up
NCT ID NCT06489860
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study planned to test a powder made from organic rice and honey as a treatment for COVID-19. It was withdrawn before enrolling any participants. The main measurements were things like humidity and levels of heavy metals in the powder, not how well it worked against the virus.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Organic rice and honey powder
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Started
-
Jan 2025
- Expected to finish
-
Feb 2025
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 year to 130 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * SARS-CoV-2 Exclusion Criteria:
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-CoV 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A phase 2, randomized, Observer-Blind, dose ranging study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1283 in participants ≥6 months to <12 years of age
- Can an old malaria drug help fight severe COVID-19?
- Can a new pill keep High-Risk COVID-19 patients out of the hospital?
- Could a five-day pill course cut COVID-19 deaths? czech nationwide data puts molnupiravir to the test.
- Millions of vaccine records scoured for rare side effects
- Scientists probe why lung disease raises COVID-19 risk